Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today)

Months after raising $25 million in a private placement, Axonyx Inc. is at it again. But this time, Axonyx has set its sights higher, looking to bring in $50 million. (BioWorld Today)

A decision reached by Trimeris Inc. and F. Hoffmann-La Roche Ltd. to halt clinical development of the early-stage HIV candidate T-1249 did not trigger a stock slide of devastating proportions for Trimeris, the company that discovered Fuzeon, a first-in-class fusion inhibitor for HIV patients. (BioWorld Today)

A decision reached by Trimeris Inc. and F. Hoffmann-La Roche Ltd. to halt clinical development of the early-stage HIV candidate T-1249 did not trigger a stock slide of devastating proportions for Trimeris, the company that discovered Fuzeon, a first-in-class fusion inhibitor for HIV patients. (BioWorld Today)